TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 67.32% ano a ano.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 69.30M.
Sobreavaliada
O PE mais recente da empresa é -1.14, em uma faixa percentil alta de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 28.86M ações, uma redução de 25.36% em relação ao trimestre anterior.
Mantido por James Simons
O Super Investidor James Simons possui 67.33K ações desta empresa.